This antibody-drug conjugate, which is administered through an IV, consists of the monoclonal antibody trastuzumab (Herceptin®) and the chemotherapy drug deruxtecan. It’s currently used to treat metastatic HER2-positive breast cancer and metastatic breast cancer that is HER2-low or ultralow and that has recurred after previous treatments.
Support research with a legacy gift. Sample, non-binding bequest language:
I give to the Breast Cancer Research Foundation, located in New York, NY, federal tax identification number 13-3727250, ________% of my total estate (or $_____).
Stay in the know with the latest research news, insights, and resources delivered to your inbox.
Follow BCRF on all the major platforms for research news, inspiring stories, and more.
